Zum Hauptinhalt springen
UB Hagen

Suchergebnisse

UB Katalog

Artikel & mehr
309 Treffer

Suchmaske

Suchtipp für den Bereich Artikel & mehr: Wörter werden automatisch mit UND verknüpft. Eine ODER-Verknüpfung erreicht man mit dem Zeichen "|", eine NICHT-Verknüpfung mit einem "-" (Minus) vor einem Wort. Anführungszeichen ermöglichen eine Phrasensuche.
Beispiele: (burg | schloss) -mittelalter, "berufliche bildung"

Das folgende Suchfeld wird hier nicht unterstützt: "Signatur / Strichcode".

Suchergebnisse einschränken oder erweitern

Aktive Suchfilter

Erscheinungszeitraum

Mehr Treffer

Weniger Treffer

Gefunden in

Art der Quelle

309 Treffer

Sortierung: 
  1. Detailansicht für Treffer 1 öffnen
    ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
    ChromaDex Media Contact: Kendall Knysch, Senior Di
    In: Business Wire, 2024-06-04, S. 2
    Zeitungsartikel
    Wie komme ich dran?
  2. Detailansicht für Treffer 2 öffnen
    Scientists generate the first complete chromosome sequences from non-human primates; Complete X and Y chromosome sequences from six primate species reveal species diversity and insights into evolution.
    In: National Institutes of Health (USA), 2024-05-29, S. 6
    Zeitungsartikel
    Wie komme ich dran?
  3. Detailansicht für Treffer 3 öffnen
    Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia; - Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol; ; - Data presented at European Atherosclerosis Society 92nd Congress and simultaneously published in the New England Journal of Medicine
    Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CF
    In: Business Wire, 2024-05-28, S. 6
    Zeitungsartikel
    Wie komme ich dran?
  4. Detailansicht für Treffer 4 öffnen
    Vesigen Highlights Key in vivo and Targeted Tropism Data Advancements for Non-Viral Delivery Platform at 2024 ASGCT and ARVO Annual Meetings; New NHP data demonstrate successful functional delivery of CRISPR/Cas9 and base editing complexes with engineered ARMMs to multiple cell types; ; Additional in vivo data demonstrate highly selective cell targeting and functional delivery of gene editing complexes using engineered ARMMs cell-specific engagers
    Investor and Media Contact: Adam Bero, Ph.D. Kenda
    In: Business Wire, 2024-05-13, S. 4
    Zeitungsartikel
    Wie komme ich dran?
  5. Detailansicht für Treffer 5 öffnen
    Talk planned on non-genetically modified soybeans
    In: Associated Press State Wire: Arkansas (AR), 2012-11-05, S. 5
    Zeitungsartikel
    Wie komme ich dran?
  6. Detailansicht für Treffer 6 öffnen
    Interest in non-genetically modified crops grows
    LAURA MAZURAK Columbia Daily Tribune
    In: Associated Press State Wire: Missouri (MO), 2013-06-27, S. 8
    Zeitungsartikel
    Wie komme ich dran?
  7. Detailansicht für Treffer 7 öffnen
    Destroy Duchenne selects DNA Nanobots as Partner to Develop Non-Viral Gene Delivery Solution for Duchenne Muscular Dystrophy; DMD patient and advocate Elijah Stacy's non-profit foundation chooses a targeted dystrophin gene therapy approach using DNA nanoparticles to overcome limitations of viral delivery systems
    Jeff Spitzner, CEO DNA Nanobots (614) 325-2103 jsp
    In: Business Wire, 2024-02-29, S. 2
    Zeitungsartikel
    Wie komme ich dran?
  8. Detailansicht für Treffer 8 öffnen
    Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors In Vivo at the Cracking the Code: The Dawn of Nucleic Acid Medicines Meeting; Robust uptake observed in photoreceptors and retinal pigment epithelium (RPE) of mice, minipigs, and non-human primates; ; Additional data demonstrate rescue of acute liver injury disease model by delivery of a gene editor to Kupffer cells
    Investor and Media Contact: Adam Bero, Ph.D. Kenda
    In: Business Wire, 2023-10-19, S. 2
    Zeitungsartikel
    Wie komme ich dran?
  9. Detailansicht für Treffer 9 öffnen
    Annogen Announces Research Project with Pfizer to Test Non-coding Genetic Sequences; Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery
    P. Victor Schut, CBO victor@annogen.bio
    In: Business Wire, 2022-12-13, S. 1
    Zeitungsartikel
    Wie komme ich dran?
  10. Detailansicht für Treffer 10 öffnen
    Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA); - Phase 3 trial is a randomized, double-blind, placebo-controlled trial of apitegromab as add-on to background SMN therapy in non-ambulatory Type 2/3 SMA; ; - Trial design is informed by the positive results from the prior TOPAZ trial, including a new exploratory analysis of patients 2-12 years old with non-ambulatory Type 2/3 SMA
    Scholar Rock Contacts: Investors Stephanie Asche
    In: Business Wire, 2021-11-30, S. 7
    Zeitungsartikel
    Wie komme ich dran?
  11. Detailansicht für Treffer 11 öffnen
    Genentech's Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
    GenentechMedia Contact:Meghan Cox, 650-467-6800orA
    In: Business Wire, 2018-10-22, S. 7
    Zeitungsartikel
    Wie komme ich dran?
  12. Detailansicht für Treffer 12 öffnen
    LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards® Scientists
    BioTime, Inc.; Peter Garcia; Chief Financial Offic
    In: Business Wire, 2013-01-30, S. 5
    Zeitungsartikel
    Wie komme ich dran?
  13. Detailansicht für Treffer 13 öffnen
    Surf Bio Announces $1.6 Million Non-Dilutive Grant; - Proceeds to Evaluate Novel Formulation Technology to Improve Thermostability and Deliverability of a Monoclonal Antibody for Low- and Middle-Income Countries -
    media@surf.bio
    In: Business Wire, 2024-04-30, S. 2
    Zeitungsartikel
    Wie komme ich dran?
  14. Detailansicht für Treffer 14 öffnen
    Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer; Findings presented by Agendia collaborators at the European Breast Cancer Conference indicate that the Research Use Only ImPrint test can predict response and non-response to common immunotherapy regimens
    Media Terri Clevenger ICR Westwicke Healthcare, PR
    In: Business Wire, 2024-03-20, S. 3
    Zeitungsartikel
    Wie komme ich dran?
  15. Detailansicht für Treffer 15 öffnen
    MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
    Investor Relations Contact +1 (872) 270-3518 ir@ma
    In: Business Wire, 2024-03-06, S. 4
    Zeitungsartikel
    Wie komme ich dran?
  16. Detailansicht für Treffer 16 öffnen
    EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies; EnLiSense's IBD Aware device offers the first groundbreaking solution for continuous, non-invasive monitoring of inflammatory bowel disease through innovative sweat-sensing technology.
    Sriram Muthukumar PR@enlisense.com
    In: Business Wire, 2024-02-15, S. 4
    Zeitungsartikel
    Wie komme ich dran?
  17. Detailansicht für Treffer 17 öffnen
    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023; Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth; ; ; ; Fourth quarter GAAP EPS of $0.64; Adjusted EPS from continuing operations of $1.25; ; ; Initiates full year 2024 guidance
    Investor Relations: Steve Willoughby steve.willoug
    In: Business Wire, 2024-02-01, S. 12
    Zeitungsartikel
    Wie komme ich dran?
  18. Detailansicht für Treffer 18 öffnen
    Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer; Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated
    Kiromic BioPharma Linda Phelan Dyson, MPH Global H
    In: Business Wire, 2024-01-29, S. 4
    Zeitungsartikel
    Wie komme ich dran?
  19. Detailansicht für Treffer 19 öffnen
    Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
    Investor Relations Noemie Djokovic, Investor Relat
    In: Business Wire, 2024-01-25, S. 3
    Zeitungsartikel
    Wie komme ich dran?
  20. Detailansicht für Treffer 20 öffnen
    Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids
    Chemify Contacts Business Development Swati Chatte
    In: Business Wire, 2024-01-18, S. 4
    Zeitungsartikel
    Wie komme ich dran?
xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -